RESEARCH ARTICLE

High prevalence of curable sexually transmitted infections among pregnant women in a rural county hospital in Kilifi, Kenya

Simon Chengo Masha1,2,3*, Elizabeth Wahome1, Mario Vaneechoutte2, Piet Cools2, Tania Crucitti4, Eduard J. Sanders1,5

1 Centre for Geographic Medicine Research–Coast, Kenya Medical Research Institute (KEMRI), Kilifi, Kenya, 2 Laboratory Bacteriology Research, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium, 3 Pwani University, Faculty of Pure and Applied Sciences, Department of Biological Sciences, Kilifi, Kenya, 4 HIV/STI Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, 5 Nuffield Department of Medicine, University of Oxford, Headington, United Kingdom

* schengo@kemri-welcome.org

Abstract

Background

Women attending antenatal care (ANC) in resource-limited countries are frequently screened for syphilis and HIV, but rarely for other sexually transmitted infections (STIs). We assessed the prevalence of curable STIs, defined as infection with either Chlamydia trachomatis or Neisseria gonorrhoeae or Trichomonas vaginalis, from July to September 2015.

Methods

In a cross-sectional study, women attending ANC at the Kilifi County Hospital, Kenya, had a urine sample tested for C. trachomatis/N. gonorrhoeae by GeneXpert® and a vaginal swab for T. vaginalis by culture. Bacterial vaginosis (BV) was defined as a Nugent score of 7–10 of the Gram stain of a vaginal smear in combination with self-reported vaginal discharge. Genital ulcers were observed during collection of vaginal swabs. All women responded to questions on socio-demographics and sexual health and clinical symptoms of STIs. Predictors for curable STIs were assessed in multivariable logistic regression.

Results

A total of 42/202 (20.8%, 95% confidence interval (CI):15.4–27.0) women had a curable STI. The prevalence was 14.9% for C. trachomatis (95% CI:10.2–20.5), 1.0% for N. gonorrhoeae (95% CI:0.1–3.5), 7.4% for T. vaginalis (95% CI:4.2–12.0), 19.3% for BV (95% CI:14.1–25.4) and 2.5% for genital ulcers (95% CI:0.8–5.7). Predictors for infection with curable STIs included women with a genital ulcer (adjusted odds ratio (AOR) = 35.0, 95% CI:2.7–461.6) compared to women without a genital ulcer, women who used water for cleaning after visiting the toilet compared to those who used toilet paper or other solid means (AOR =
4.1, 95% CI:1.5–11.3), women who reported having sexual debut ≤ 17 years compared to women having sexual debut ≥ 18 years (AOR = 2.7, 95% CI:1.1–6.6), and BV-positive women (AOR = 2.7, 95% CI:1.1–6.6) compared to BV-negative women.

### Conclusion
One in five women attending ANC had a curable STI. These infections were associated with genital ulcers, hygiene practices, early sexual debut and bacterial vaginosis.

### Introduction
Sexually transmitted infections (STIs) are a major public health concern globally and especially among women in resource-limited countries [1]. Common curable STIs among women in sub-Saharan Africa (sSA) include *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* [2]. Additionally, bacterial vaginosis (BV), which has been associated with an increased risk of incident infection with *C. trachomatis* and *N. gonorrhoeae* [3, 4], is highly prevalent [5]. These curable STIs and BV have been associated with a number of adverse pregnancy outcomes such as spontaneous abortion, ectopic pregnancy, preterm delivery, low birth weight, stillbirth, postpartum sepsis, and congenital infection [6]. Infants born of mothers with genital *C. trachomatis* are at an increased risk of suffering from neonatal pneumonia and ophthalmia neonatorum [7]. At present the efficacy of neonatal ocular prophylaxis with erythromycin for prevention of *C. trachomatis* ophthalmia is not clear [8]. These associated sequelae of STIs hence necessitate prevention and management of curable STIs and BV, especially during pregnancy.

Pregnant women attending antenatal care (ANC) in resource-limited countries are frequently screened for syphilis [9] and HIV [10], but rarely for other curable STIs or BV. Moreover, curable STIs and BV are associated with increased acquisition and transmission of HIV [11–13]. Among pregnant HIV positive women *C. trachomatis* is associated with increased risk of HIV mother-to-child transmission [14]. Many resource-limited countries have adopted the World Health Organization’s syndromic approach for the management of curable STI [15]. This syndromic approach is deficient in both sensitivity and specificity because STIs may be asymptomatic or have non-specific clinical signs and symptoms [16, 17].

There is a paucity of epidemiological and risk factor data on curable STIs among women residing in rural areas, including among pregnant women in coastal Kenya. Most of the recent information about the prevalence of curable STIs among women in Kenya has been from studies done among high-risk individuals [18], women residing in cities [19, 20] or from regions with high incidence of HIV [13]. Consequently, we assessed the prevalence and predictors of curable STIs in pregnant women attending ANC at a rural county hospital in Coastal Kenya.

### Methods
This was a cross-sectional study conducted from July to September 2015, at the ANC clinic of the Kilifi County Hospital (KCH), Kenya, a clinic attended to by approximately 4,000 women annually [21]. We aimed to enroll a convenience sample of 350 consecutive pregnant women to identify 20–25 women with *T. vaginalis* for detailed molecular studies of *T. vaginalis* and assessment of the vaginal microbiome. Here, we report on a sub-study of 202 women who were tested for curable STIs, i.e. *C. trachomatis*, *N. gonorrhoeae*, *T. vaginalis*, and for BV.
Procedures

Recruitment: A nurse at the ANC clinic provided general information about the study to women who had completed their ANC visit. Women interested to know more about the study were invited to participate and up to nine consecutive women were enrolled per day.

Inclusion criteria: Women were eligible if they met the following criteria: age 18–45 years, gestation ≥ 14 weeks, resident of the Kilifi Health and Demographic Surveillance area [22] and willing to undergo free STI and BV screening procedures.

Study procedures: Consenting women underwent a short private interview with the nurse at the ANC clinic using a structured questionnaire capturing symptoms of vaginal infections. This was followed by a collection of vaginal swabs by the ANC nurse. During the collection of vaginal swabs, the nurse observed for abnormal vaginal discharge and genital ulcers. Three vaginal swabs were collected, by inserting one swab at a time approximately 2 inches into the vaginal opening and gently turning around twice ensuring rubbing the swab against the vaginal wall.

The first swab was used for BV diagnosis and vaginal smears were prepared by rolling the swab onto a microscope glass slide. Slides were air-dried at the clinic before being transported to the laboratory for heat fixation followed by Gram staining and microscopy using the scoring system described by Nugent [23]. Women who self-reported discharge and had a Nugent score of 7–10 were considered BV-positive, and were treated as recommended [8]. Women with a Nugent score of 7–10 but without discharge were considered BV-negative.

The second swab was used to diagnose *T. vaginalis* using a commercially available *T. vaginalis* InPouch™ system (BioMed Diagnostics, White City, Oregon, USA). The vaginal swab was inoculated in the upper-chamber of the InPouch at the clinic. The inoculated InPouch was transferred to the laboratory for direct microscopy of the upper chamber, after which the upper chamber was merged with the lower chamber and incubated at 37°C. Daily microscopy was performed and samples with motile trichomonads within 5 days of culture were considered positive for *T. vaginalis*.

The third swab was placed in a sterile labeled 2 ml Eppendorf tube, the swab shaft was broken by bending the shaft against the neck of the Eppendorf tube. The bottom portion of the swab with the specimen was transported to the laboratory where it was immediately stored at -80°C for molecular studies of the vaginal microbiome. No transport or freezing medium was added.

Women provided fresh first catch urine for *C. trachomatis* and *N. gonorrhoeae* testing, that was performed by the GeneXpert® CT/NG Assay (Cepheid, Sunnyvale, California), according to the manufacturer’s instructions.

Results for *C. trachomatis*, *N. gonorrhoeae*, for *T. vaginalis* direct microscopy and for BV were reported on the same day of the visit, and STI and BV treatment was offered according to Kenyan national guidelines [24], except for treatment of *N. gonorrhoeae* where ceftriaxone was used in place of quinolones [25]. Women who were negative on *T. vaginalis* direct microscopy but positive on culture were contacted to return to the ANC clinic for treatment immediately after the culture turned positive. Treatment was also offered for the partners of the women with curable STIs.

Syphilis and HIV test results were obtained from each participant’s ANC records. Syphilis results were based on testing for treponemal antibodies only, done at the hospital laboratory using a commercial test kit Advanced Quality One Step Anti-TP (InTec products INC, Xiamen, China). Rapid HIV testing was done by the Alere Determine HIV-1/2 kit (Alere Medical Co Ltd, Chiba, Japan), the First response HIV 1-2-0 kit (Premier Medical Corporation Limited, Daman, India) was used to confirm positive results, and the Uni-Gold kit (Trinity Biotech, Wicklow, Ireland) was used to resolve any discordant test results.
After clinical procedures were completed, all study participants were interviewed. The interviews were conducted in Kiswahili by a trained female fieldworker. The questionnaire covered sociodemographic, hygienic and sexual behavior questions. These included age, education level, marital status, number of children, occupation, consumption of alcohol, consumption of tobacco and other substances, age at first sex, number of sexual partners, history of STIs, and hygiene and sanitary practices.

Ethical considerations
The study was approved by the KEMRI Scientific and Ethics Review Unit (#3022). All participants provided written informed consent for study participation. Permission to use hospital records on syphilis and HIV status was obtained from Kilifi County Health department.

Data analysis
Data were entered in the REDCap™ electronic data capture tool, version 6.5.0 (Vanderbilt University, Nashville, Tennessee). Prevalence of STIs was determined as the number of participants with either *C. trachomatis*, *N. gonorrhoeae* and/or *T. vaginalis* out of 202 women that could be tested, expressed as a percentage. Exact 95% binomial confidence intervals (CIs) were calculated for prevalence estimates. Bivariable logistic regression was used to determine associations of sociodemographic, hygienic, behavioral and clinical characteristics with curable STIs. Variables significant at $p \leq 0.1$ in bivariable analysis were entered into a multivariable model to identify independent associations. Crude odds ratios (COR) and adjusted odds ratios (AOR) were calculated. These statistical analyses were done using STATA version 13.1 (StataCorp, College Station, Texas).

Results
From June to September 2015, a total of 373 women were invited to participate in the study. Twenty-three (6.2%) women declined to participate citing no interest in research, lacking time or having no permission from spouse/partner as the main reasons. Of the 350 women enrolled, 148 (42.3%) women did not have *C. trachomatis* and *N. gonorrhoeae* tests performed due the unavailability of the tests at the beginning of the study. Therefore, a total of 202 women were tested for *C. trachomatis*, *N. gonorrhoeae*, *T. vaginalis* and BV and were included in this sub-analysis (Fig 1).

Characteristics of the study population
The median age and gestation age including the interquartile range (IQR) for the participants was 26 (22–31) years and 24 (20–28) weeks respectively. The majority of the participants were married (93.6%) and Christian (72.3%). A quarter of the participants had secondary school education and above. The median age and IQR of sexual debut was 18 (16–20) years, although 20.8% of the participants were not sure or did not respond to this question. Forty-two percent of the participants had given birth before and the number of children ranged from 1–7. Sixty-two percent of the participants had previously experienced signs/symptoms associated with reproductive tract infection and one third had ever received syndromic treatment for genital signs or symptoms of infection. The socio-demographic characteristics of the participants are summarized in Table 1.

Prevalence of curable STIs, BV, HIV and syphilis
A total of 20.8% (42/202) (95% confidence interval (CI): 15.4–27.0) women had a curable STI and 19.4% (39/202) (95% CI: 14.2–25.6) women had BV i.e. Nugent score of 7–10 and reported...
vaginal discharge. The prevalence was 14.9% for \textit{C. trachomatis} (95% CI: 10.2–20.5), 1.0% for \textit{N. gonorrhoeae} (95% CI: 0.1–3.5) and 7.4% for \textit{T. vaginalis} (95% CI: 4.2–12.0) (Fig 1). Five (11.9%) women had more than one STI, while 13 (31%) out of the 42 women with a curable STI also had BV. Only two women (1.0%) had asymptomatic BV and none of them had a curable STI (data not shown).

Thirteen women were HIV-positive, a prevalence of 6.4% (95% CI: 3.4–10.8), including four (2.0%; 95% CI: 0.5–5.0) women who were newly diagnosed. Of note, HIV prevalence in 82 women aged 18–24 vs. 120 women aged ≥ 25 years was 0% vs. 10.8% (p = 0.002). All nine HIV positive women who knew their status were on anti-retroviral therapy. Among the 13 women with HIV, three women had curable STIs, i.e. a prevalence of 23.1% (95% CI: 5.0–53.8). All women with HIV and a curable STI also had BV. The prevalence of curable STIs, or BV in the 13 women with HIV was not statistically significantly different from that of the 189 women without HIV (data not shown).

Two women had treponemal antibodies, a prevalence of 1.0% (95% CI: 0.1–3.6). Prevalence of HIV, treponemal antibodies and \textit{T. vaginalis} for the 148 women who were not tested for \textit{C. trachomatis} and \textit{N. gonorrhoeae} was not statistically significantly different than the prevalence of HIV, syphilis, and \textit{T. vaginalis} in the 202 tested for \textit{C. trachomatis} and \textit{N. gonorrhoeae} in the sub-study.

**Clinical signs and symptoms**

The most commonly self-reported symptoms amongst all participants were vaginal discharge (73.8%) and lower abdominal pain (46.5%). However, during collection of specimen by the study nurse, only 17.3% of the participants had an abnormal discharge (defined as excess
Table 1. Socio-demographic, hygienic, and behavioral characteristics of 202 women attending antenatal care and tested for sexually transmitted infections and bacterial vaginosis in Kilifi County Hospital, Kenya, July-September 2015.

| Demographic characteristics | Total n = 202 | Positive for curable STIs n = 42 (%) |
|-----------------------------|--------------|-------------------------------------|
| **Age group (Years)**       |              |                                     |
| 18–24                       | 82           | 24 (29.3)                           |
| ≥ 25                        | 120          | 18 (15.0)                           |
| **Religion**                |              |                                     |
| Christian                   | 146          | 28 (19.2)                           |
| Muslim                      | 28           | 7 (25.0)                            |
| Other/None                  | 28           | 7 (25.0)                            |
| **Education**               |              |                                     |
| None                        | 35           | 7 (20.0)                            |
| Primary                     | 118          | 26 (22.0)                           |
| Secondary/Tertiary          | 49           | 9 (18.4)                            |
| **Marital status**          |              |                                     |
| Single                      | 13           | 5 (38.5)                            |
| Married                     | 189          | 37 (19.6)                           |
| **Residency**               |              |                                     |
| Living with partner         | 138          | 27 (19.6)                           |
| Not living with the partner | 64           | 15 (23.4)                           |
| **Employment status**       |              |                                     |
| Employed/self-employed      | 115          | 20 (17.4)                           |
| Unemployed                  | 87           | 22 (25.3)                           |
| **Parity**                  |              |                                     |
| 0                           | 58           | 15 (25.9)                           |
| 1–2                         | 69           | 17 (24.6)                           |
| 3+                          | 75           | 10 (13.3)                           |
| **Gestational age (weeks)** |              |                                     |
| 14–25                       | 114          | 24 (21.1)                           |
| ≥ 26                        | 87           | 18 (20.7)                           |
| **Hygiene characteristics** |              |                                     |
| Toilet type                 |              |                                     |
| Flushing toilet             | 75           | 15 (20.0)                           |
| Pit latrine                 | 105          | 22 (21.0)                           |
| Bush/Other                  | 22           | 5 (22.7)                            |
| Mode of cleaning after visiting the toilet | | |
| Tissue paper/other solid materials | 64 | 7 (10.9) |
| Water                       | 138          | 35 (25.4)                           |
| **Vaginal washing when bathing ‡** | | |
| External                    | 32           | 6 (18.8)                            |
| Internal                    | 166          | 35 (21.1)                           |
| **Behavioral characteristics** |            |                                     |
| Sexual debut age (years)    |              |                                     |
| < 17                        | 64           | 21 (32.8)                           |
| ≥ 18                        | 96           | 14 (14.6)                           |
| Don’t know/no response      | 42           | 7 (16.7)                            |
| **Number of lifetime sex partners** | | |
| 1                           | 96           | 16 (16.7)                           |

(Continued)
Table 1. (Continued)

| Total n = 202 | Positive for curable STIs n = 42 (%) |
|---------------|-------------------------------------|
| 2+            | 106                                 | 26 (24.5) |

Partner had other sexual partners in the last 6 months

| No | 182 | 38 (20.9) |
| Yes | 20  | 4 (20.0) |

Alcohol consumption ever

| No | 160 | 35 (21.9) |
| Yes | 42  | 7 (16.7) |

Tobacco smoking/chewing ever

| No | 191 | 41 (21.5) |
| Yes | 11  | 1 (9.1) |

Drugs/substance use ever

| No | 194 | 39 (20.1) |
| Yes | 8  | 3 (37.5) |

Sexually transmitted infections/ reproductive tract infection

| HIV | Negative | 189 | 39 (20.6) |
| Yes | 13 | 3 (23.1) |

| Syphilis*** | Negative | 198 | 42 (21.2) |
| Positive | 2  | 0 (0.0) |

Bacterial vaginosis*

| Negative | 162 | 29 (17.9) |
| Positive | 39  | 13 (33.3) |

Clinical signs and symptoms of STI

| Previous history of vaginal discharge | No | 75 | 13 (17.3) |
| Yes | 127 | 29 (22.8) |

| Previous syndromic treatment of genital infection | No | 136 | 28 (20.6) |
| Yes | 66  | 14 (21.2) |

| Current vaginal discharge (self-reported) | No | 52 | 10 (19.2) |
| Yes | 149 | 32 (21.5) |

| Abnormal vaginal discharge foul smell/color (observed) | No | 165 | 32 (19.4) |
| Yes | 36  | 10 (27.8) |

| Dysuria | No | 159 | 32 (20.1) |
| Yes | 42  | 10 (23.8) |

| Dyspareunia | No | 150 | 29 (19.3) |
| Yes | 51  | 13 (25.5) |

| Vaginal itching | No | 146 | 31 (21.2) |
| Yes | 55  | 11 (20.0) |

(Continued)
discharge/foul smelling discharge/colored discharge) upon examination. Five (2.5%) women had genital ulcers upon examination, of which 4 (9.6%) of the 42 women with a curable STI vs. 1 (0.6%) of the 159 women without a curable STI (p = 0.001). None of the women with genital ulcers had HIV or treponemal antibodies. Other self-reported clinical signs or symptoms were not associated with curable STIs.

Based on symptoms routinely used in syndromic management of STIs (i.e. genital ulcer, lower abdominal pain or abnormal vaginal discharge), 45.2% of the 42 women with curable STIs were asymptomatic.

Risk factors/predictors
In bivariable analysis, curable STIs were more common among participants who were ≤24 years, had less than 3 children, had a sexual debut ≤17 years, used water to clean themselves after visiting the toilet, had a genital ulcer or were BV positive (Table 2).

In multivariable analysis, independent predictors associated with curable STIs included women with a genital ulcer (AOR = 35.0, 95% CI: 2.7–461.6) compared to women without a genital ulcer, women who used water for cleaning after visiting the toilet compared to those who used toilet paper or other solid materials (AOR = 4.1, 95% CI: 1.5–11.3), women who reported having sexual debut ≤17 years compared to women having sexual debut ≥18 years (AOR = 2.7, 95% CI: 1.1–6.6), and BV-positive women (AOR = 2.7, 95% CI: 1.1–6.6) compared to BV-negative women (Table 2).

Discussion
We found that one in five out of 202 pregnant women attending the ANC at the Kilifi County Hospital, Kenya, during the period July to September 2015 had at least one curable STI. The
Table 2. Bivariable and multivariable analysis of socio-demographic, hygienic, behavioral, and clinical characteristics of pregnant women with curable sexually transmitted infections attending antenatal clinic at Kilifi County Hospital, July—September 2015 (n = 202).

| Demographic characteristics | Curable STIs n(%) | Bivariable analysis | Multivariable analysis |
|-----------------------------|-------------------|---------------------|------------------------|
|                             | Curable STIs n(%) | COR (95% C.I)       | P-value                | AOR (95% C.I) | P-value |
| **Age group (Years)**       |                   |                     |                        |              |
| 18–24                       | 24 (29.3)         | 2.3 (1.2–4.7)       | 0.016                  | 1.8 (0.7–4.4) | 0.226   |
| ≥ 25                        | 18 (15.0)         | Ref                 |                        |              |
| **Religion**                |                   |                     |                        |              |
| Christian                   | 28 (19.2)         | Ref                 |                        |              |
| Muslim                      | 7 (25.0)          | 1.4 (0.5–3.6)       | 0.483                  | -            |
| Other/None                  | 7 (25.0)          | 1.4 (0.5–3.6)       | 0.483                  | -            |
| **Education**               |                   |                     |                        |              |
| None                        | 7 (20.0)          | Ref                 |                        |              |
| Primary                     | 26 (22.0)         | 1.1 (0.4–2.9)       | 0.797                  | -            |
| Secondary/Tertiary          | 9 (18.4)          | 0.9 (0.3–2.7)       | 0.851                  | -            |
| **Marital status**          |                   |                     |                        |              |
| Single                      | 5 (38.5)          | Ref                 |                        |              |
| Married                     | 37 (19.6)         | 0.4 (0.1–1.3)       | 0.115                  | -            |
| **Residency**               |                   |                     |                        |              |
| Living with partner         | 27 (19.6)         | Ref                 |                        |              |
| Not living with partner     | 15 (23.4)         | 1.3 (0.6–2.6)       | 0.529                  | -            |
| **Employment status**       |                   |                     |                        |              |
| Employed/self-employed      | 20 (17.4)         | Ref                 |                        |              |
| Unemployed                  | 22 (25.3)         | 1.6 (0.8–3.2)       | 0.173                  | -            |
| **Parity**                  |                   |                     |                        |              |
| 0                           | 15 (25.9)         | 2.3 (0.9–5.5)       | 0.071                  | 2.7 (0.8–8.9) | 0.111   |
| 1–2                         | 17 (24.6)         | 2.1 (0.9–5.0)       | 0.087                  | 1.9 (0.7–5.2) | 0.237   |
| 3+                          | 10 (13.3)         | Ref                 |                        |              |
| **Gestational age (weeks)** |                   |                     |                        |              |
| 14–25                       | 23 (20.5)         | Ref                 |                        |              |
| ≥ 26                        | 18 (20.7)         | 1.0 (0.5–2.0)       | 0.979                  | -            |
| **Hygiene characteristics** |                   |                     |                        |              |
| **Toilet type**             |                   |                     |                        |              |
| Flushing toilet             | 15 (20.0)         | Ref                 |                        |              |
| Pit latrine                 | 22 (21.0)         | 1.1 (0.5–2.2)       | 0.876                  | -            |
| Bush/Other                  | 5 (22.7)          | 1.2 (0.4–3.7)       | 0.781                  | -            |
| **Mode of cleaning after visiting the toilet** | | | | |
| Tissue paper/other solid material | 7 (10.9)      | Ref                 |                        |              |
| Water                       | 35 (25.4)         | 2.8 (1.2–6.6)       | 0.022                  | 4.1 (1.5–11.3) | 0.007   |
| **Vaginal washing when bathing** | | | | |
| External                    | 6 (18.8)          | Ref                 |                        |              |
| Internal                    | 35 (21.1)         | 1.2 (0.4–3.0)       | 0.766                  | -            |
| **Behavioral characteristics** | | | | |
| **Sexual debut age (years)** |                   |                     |                        |              |
| ≤ 17                        | 21 (32.8)         | 2.9 (1.3–6.2)       | 0.007                  | 2.7 (1.1–6.6) | 0.026   |
| ≥ 18                        | 14 (14.6)         | Ref                 |                        |              |
| Don’t know/no response      | 7 (16.7)          | 1.2 (0.4–3.2)       | 0.754                  | -            |
| **Number of lifetime sex partners** | | | | |
| 1                           | 16 (16.7)         | Ref                 |                        |              |

(Continued)
Table 2. (Continued)

| Demographic characteristics                                                                 | Curable STIs n(%) | Bivariable analysis | Multivariable analysis |
|--------------------------------------------------------------------------------------------|------------------|---------------------|------------------------|
|                                                                                           |                  | COR (95% C.I)       | P-value                | AOR (95% C.I) | P-value |
| 2                                                                                           | 26 (24.5)        | 1.6 (0.8–3.3)       | 0.171                  | -            | -       |
| Partner has had other sexual partner(s) in the last 6 months                               |                  |                     |                        |              |         |
| No                                                                                         | 38 (20.9)        | 1.1 (0.3–3.3)       | 0.927                  | -            | -       |
| Yes                                                                                        | 4 (20.0)         | Ref                 |                        |              |         |
| Alcohol consumption ever                                                                  |                  |                     |                        |              |         |
| No                                                                                         | 35 (21.9)        | 1.4 (0.6–3.4)       | 0.461                  | -            | -       |
| Yes                                                                                        | 7 (16.7)         | Ref                 |                        |              |         |
| Tobacco smoking/chewing ever                                                               |                  |                     |                        |              |         |
| No                                                                                         | 41 (21.5)        | 2.7 (0.3–22.0)      | 0.344                  | -            | -       |
| Yes                                                                                        | 1 (9.1)          | Ref                 |                        |              |         |
| Drugs/Substance use ever                                                                  |                  |                     |                        |              |         |
| No                                                                                         | 39 (20.1)        | 0.4 (0.1–1.8)       | 0.248                  | -            | -       |
| Yes                                                                                        | 3 (37.5)         | Ref                 |                        |              |         |
| Clinical characteristics                                                                   |                  |                     |                        |              |         |
| HIV status                                                                                 |                  |                     |                        |              |         |
| Negative                                                                                   | 39 (20.6)        | Ref                 |                        |              |         |
| Positive                                                                                  | 3 (23.1)         | 1.2 (0.3–4.4)       | 0.834                  | -            | -       |
| Bacterial vaginosis                                                                        |                  |                     |                        |              |         |
| Negative                                                                                   | 29 (17.9)        | Ref                 |                        |              |         |
| Positive                                                                                  | 13 (33.3)        | 2.3 (1.1–5.0)       | **0.036**              | **2.7 (1.1–6.6)** | **0.031** |
| Clinical signs and symptoms of STI                                                          |                  |                     |                        |              |         |
| Previous history of vaginal discharge                                                      |                  |                     |                        |              |         |
| No                                                                                         | 13 (17.3)        | Ref                 |                        |              |         |
| Yes                                                                                        | 29 (22.8)        | 1.4 (0.7–2.9)       | 0.353                  | -            | -       |
| Previous syndromic treatment of genital infection                                           |                  |                     |                        |              |         |
| No                                                                                         | 28 (20.5)        | Ref                 |                        |              |         |
| Yes                                                                                        | 14 (21.2)        | 1.0 (0.5–2.1)       | 0.918                  | -            | -       |
| Current vaginal discharge (self-reported)                                                   |                  |                     |                        |              |         |
| No                                                                                         | 10 (19.2)        | Ref                 |                        |              |         |
| Yes                                                                                        | 32 (21.5)        | 1.1 (0.5–2.5)       | 0.732                  | -            | -       |
| Abnormal vaginal discharge (observed)                                                       |                  |                     |                        |              |         |
| No                                                                                         | 32 (19.4)        | Ref                 |                        |              |         |
| Yes                                                                                        | 10 (27.8)        | 1.6 (0.7–3.6)       | 0.265                  | -            | -       |
| Dysuria                                                                                   |                  |                     |                        |              |         |
| No                                                                                         | 32 (20.1)        | Ref                 |                        |              |         |
| Yes                                                                                        | 10 (23.8)        | 1.2 (0.6–2.8)       | 0.602                  | -            | -       |
| Dyspareunia                                                                               |                  |                     |                        |              |         |
| No                                                                                         | 29 (19.3)        | Ref                 |                        |              |         |
| Yes                                                                                        | 13 (25.5)        | 1.4 (0.7–3.0)       | 0.352                  | -            | -       |
| Vaginal itching                                                                            |                  |                     |                        |              |         |
| No                                                                                         | 31 (21.2)        | Ref                 |                        |              |         |
| Yes                                                                                        | 11 (20.0)        | 0.9 (0.4–2.0)       | 0.848                  | -            | -       |
| Lower abdominal pain                                                                       |                  |                     |                        |              |         |
| No                                                                                         | 24 (22.4)        | Ref                 |                        |              | -       |
| Yes                                                                                        | 18 (19.1)        | 0.8 (0.4–1.6)       | 0.568                  | -            | -       |
| Genital warts                                                                             |                  |                     |                        |              |         |
| No                                                                                         | 40 (20.4)        | Ref                 |                        |              | -       |
| Yes                                                                                        | 2 (40.0)         | 2.6 (0.4–16.1)      | 0.304                  | -            | -       |

(Continued)
A high burden of curable STIs was mostly due to cases of *C. trachomatis* (14.9% of women) and *T. vaginalis* (7.4% of women). We also found approximately 19.4% of the women to have BV, defined as the presence of vaginal discharge in combination with a Nugent score ≥7. Four out of the 5 women with genital ulcers also had a curable STI. Our study documented that having genital ulcers, cleaning with water as opposed to use of toilet paper after visiting the toilet, early sexual debut, and BV were strongly associated with the presence of curable STIs.

The high prevalence (14.9%) of *C. trachomatis* found in this study is comparable to a prevalence of 13% (95% CI: 8.6–16.8) among women seeking family planning services in Nairobi, Kenya [20] and 9.9% (95% CI: 7.2–13.2) among women in a multi-country (Kenya, Rwanda and South Africa) cross-sectional study [26]. Two other recent studies reported lower prevalence rates of *C. trachomatis*: 5.6% (95% CI: 4.4–7.0) among 1300 HIV-seronegative ANC-attending women at two district hospitals in rural western Kenya [13], and 6.0% (95% CI: 3.6–9.3) in another study among 300 women attending outpatient clinics in Nairobi [27]. Since the high prevalence of *C. trachomatis* among pregnant women may likely reflect ongoing transmission of *C. trachomatis* among the general rural population in Kilifi, further studies confirming the high prevalence and ongoing *C. trachomatis* transmission among this population would be helpful. *Chlamydia* infection has been found to be an independent predictor of HIV-1 acquisition in a recent study from western Kenya, with also syphilis, yeast infection/colonisation and BV showing strong associations with incident HIV-1 infection [13].

We documented a prevalence of *T. vaginalis* (7.4%) comparable to 6.0% among HIV-seronegative ANC-attending women in rural western Kenya [13], and 7.7% among women attending a child-health clinic in Mombasa, Kenya [28]. In vitro evidence suggests that *T. vaginalis* may alter the vaginal microbiome towards BV [29]. *T. vaginalis* has also been associated with increased viral shedding and increased acquisition of HIV [30, 31], potentially contributing to a significant number of additional HIV infections globally [31].

The prevalence of HIV-1 (6.4%) in this study was substantial, with all known and newly diagnosed cases occurring amongst the 120 women ≥25 years. In Coastal Kenya, HIV-1 prevalence estimates in women aged 15–24 years decreased from 5.7% in 2007 to 2.0% in 2012 (p = 0.026) [32]. Our results suggest a further decline in HIV-1 prevalence, among women ≤ 24 years.
A relatively low prevalence of *N. gonorrhoeae* (1%) and treponemal antibodies (1%) were found in our study. The prevalence of treponemal antibodies was similar to the study among HIV-seronegative ANC-attending women in rural western Kenya, [13] while the *N. gonorrhoeae* prevalence in the latter study was 3.0%.

BV diagnosis in our study was based on an *a priori* self-report of vaginal discharge in combination with a Nugent score of $\geq 7$ (while only 2 (1%) women had asymptomatic BV). Women with BV had an almost 3-fold higher risk of infection with a curable STIs than women without BV, comparable to other studies [4, 33]. It might be advisable to better document the presence of BV. However, general screening for BV among all women attending ANC, using the Nugent score [23] or Amsel’s criteria [34], would require significant commitment of resources and staff.

Using simple point of care testing, Madhivanan et al. [35] demonstrated that a vaginal pH $>4.5$ and a positive whiff test had a sensitivity of 83% but a specificity of only 47% for diagnosing BV. Although, not specific this approach may be adopted for BV screening in resource poor settings. Alternatively, presumptive treatment with intravaginal metronidazole (750 mg) plus miconazole (200 mg) for five consecutive nights each month for 12 months was shown to be effective to improve vaginal health and to decrease susceptibility to bacterial STIs, in a recent trial among non-pregnant women [36], but the frequency of treatment would make it challenging to upscale this intervention.

Our findings reinforce the need to integrate STI services at ANC. Screening for *T. vaginalis* can be achieved at a relatively affordable cost (US $ 5), making screening for *T. vaginalis* potentially feasible. Recent acquisition by the Kenyan government of over 120 GeneXpert IV machines for county and sub-county hospitals for tuberculosis testing [37], has potentially expanded the diagnostic capacity for curable STIs using the same testing platform at larger hospitals. However, the cost of the *C. trachomatis* and *N. gonorrhoeae* test kits are currently high. Without assay costs becoming considerably less expensive, it seems unlikely that ANC-attending women will be routinely tested for *C. trachomatis* and *N. gonorrhoeae*. Cost-effective studies have played an important role of informing policy on the gains of syphilis screening in pregnancy while minimizing on the expenditure [38]. Such cost-effectiveness studies of ANC screening and treatment of *C. trachomatis*, *N. gonorrhoeae*, and *T. vaginalis* should be conducted in resource poor settings.

Treatment of STIs in both infected persons and their partner is pivotal for STI management, ensuring reduction in cases of reinfection or non-resolving infections and prevention of adverse outcomes [8]. In our study a presumptive patient delivered partner treatment approach was adopted. Despite the fact that we did not collect information on the number of partners who were treated, this approach has been shown to be acceptable and feasible among pregnant women in Kenya [39].

Early sexual debut was strongly associated with curable STIs in our study population, similar to findings in other studies [40, 41]. Kilifi county is one of the poorest counties in Kenya, characterized by low literacy levels mostly among women, young age at marriage of women, and high fertility rates [42]. Structural changes focusing on the economic empowerment of communities, including improved access to education, and legislation protecting women from early marriage will be necessary to reduce the high burden of curable STIs among pregnant women.

A salient predictor of curable STIs in our study population was the use of water to clean after visiting the toilet as compared to those women who reported to use toilet paper or other solid materials. Unfortunately, our hygiene question did not distinguish urinating from defecating, or inquired whether the cleaning mode included both anus and vagina. It is possible that such cleaning transported bacteria from the perianal area to the vagina, as pathogens causing curable STIs may be found in paragenital areas [43]. Moreover, there is a strong correspondence in
bacterial species and loads between the vagina and rectum of pregnant women [44]. McClelland et al. [31] showed that vaginal washing increased risk of HIV-1 acquisition among African women. Although, we did not assess whether water used by our study participants was shared, sharing of water may potentially lead to contamination of the vagina [45]. Pereira-Neves and Benchimol [46] showed in vitro that T. vaginalis remained viable and infective in swimming pool water samples for several hours. Further research is required to investigate the potential role that sanitary and hygiene practices may play in women with high prevalence of curable STIs and BV.

Observed genital ulcers had the strongest association with curable STIs, and were found in 2.5% of study participants. Presumptively treating curable STIs on the basis of observed genital ulcers in pregnant women would have treated ~10% of the curable STIs in our study. Studies examining microbial aetiology of genital ulcer disease, have shown that genital ulcers can be attributed to several sexually transmitted pathogens with most cases being attributed to Herpes Simplex virus type 2 [47, 48]. Genital ulcers were also identified as the strongest predictor of acute HIV acquisition in attendees of STD clinics who initially had HIV-seronegative or discordant rapid test results [49]. While in our study no women with genital ulcers had HIV, observing genital ulcers in women may help initiate risk reduction during ANC counselling and targeted acute HIV screening [50].

Our study had some limitations. First, our study only included a relatively small sample of pregnant women limiting the precision of our prevalence estimates. Second, we only included adult women and were not able to enroll pregnant women who were minors. Minors are potentially more vulnerable and may have presented with different STIs. Third, we included only women residing within the Kilifi Health and Demographic Surveillance Area [22], and therefore will have excluded women from outside the surveillance area who may have different health characteristics. Fourth, our hygiene and sanitary questions were few, and limited [51].

Finally, this was a cross-sectional study, only allowing for an assessment of associations and we did not collect data on pregnancy outcomes.

Despite these limitations, we showed that there is high prevalence of curable STIs among pregnant women attending an antenatal clinic at Kilifi County Hospital, Kenya. Curable STIs were associated with genital ulcers, hygienic practices, early sexual debut and BV. We recommend that antenatal care programs consider strengthening their diagnostic screening for curable STIs and BV.

Acknowledgments

We would like to thank the study participants and a special thanks to all nurses at the ANC clinic of the Kilifi County Hospital and to Sarah Kioko (field worker). This manuscript was submitted for publication with permission from the Director of the Kenya Medical Research Institute (KEMRI).

Author Contributions

Conceptualization: SCM MV EJS.
Data curation: SCM EW.
Formal analysis: SCM EW.
Funding acquisition: SCM MV EJS.
Investigation: SCM.
Project administration: SCM EJS.
Supervision: SCM EJS.
Validation: SCM.
Visualization: SCM EW.
Writing – original draft: SCM.
Writing – review & editing: SCM EW MV PC TC EJS.

References
1. World Health Organization. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections, Overview and Estimates. WHO, 2008 ISBN 978 92 4 150383 9.
2. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS one. 2015; 10(12):e0143304. Epub 2015/12/10. PubMed Central PMCID: PMCPMC4672879. https://doi.org/10.1371/journal.pone.0143304 PMID: 26646541
3. Ness RB, Kip KE, Soper DE, Hillier S, Stamm CA, Sweet RL, et al. Bacterial vaginosis (BV) and the risk of incident gonococcal or chlamydial genital infection in a predominantly black population. Sex Transm Dis. 2005; 32(7):413–7. Epub 2005/06/25. PMID: 15976598
4. Abbi NS, Reddy T, Ramjee G. Prevalent bacterial vaginosis infection—a risk factor for incident sexually transmitted infections in women in Durban, South Africa. International journal of STD & AIDS. 2015. Epub 2015/11/06.
5. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. American Journal of Obstetrics & Gynecology. 209(6):505–23.
6. Mullick S, Watson-Jones D, Bekinsinska M, Mabey D. Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sexually transmitted infections. 2005; 81(4):294–302. PubMed Central PMCID: PMCPMC1745010. https://doi.org/10.1136/sti.2002.004077 PMID: 16061534
7. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis Infection in Pregnancy: The Global Challenge of Preventing Adverse Pregnancy and Infant Outcomes in Sub-Saharan Africa and Asia. BioMed Research International. 2016; 2016:9315757. https://doi.org/10.1155/2016/9315757 PMID: 27144177
8. Kimberly A. Workowski, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2015, Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Vol. 64 / No. 3.
9. Kuznik A, Habib AG, Manabe YC, Lamorde M. Estimating the public health burden associated with adverse pregnancy outcomes resulting from syphilis infection across 43 countries in sub-Saharan Africa. Sex Transm Dis. 2015; 42(7):369–75. PubMed Central PMCID: PMCPMC4520246. https://doi.org/10.1097/OLQ.0000000000000291 PMID: 26222749
10. Gunn JKL, Asaolu IO, Center KE, Gibson SJ, Wightman P, Ezeanolue EE, et al. Antenatal care and uptake of HIV testing among pregnant women in sub-Saharan Africa: a cross-sectional study. Journal of the International AIDS Society. 2016; 19(1). PubMed Central PMCID: PMCPMC4718968.
11. Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. The Journal of infectious diseases. 2008; 197(4):548–54. Epub 2008/02/16. https://doi.org/10.1086/526496 PMID: 18275275
12. Buve A, Jespers V, Crucitti T, Fichorova RN. The vaginal microbiota and susceptibility to HIV. Aids. 2014; 28(16):2333–44. Epub 2014/11/13. PMID: 25389548
13. Knuthia J, Drake AL, Materno D, Richardson BA, Zeh C, Osborn L, et al. HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS. 2015; 29(15):2025–33. Epub 2015/09/10. PubMed Central PMCID: PMCPMC4692052. https://doi.org/10.1097/QAD.0000000000000793 PMID: 26352880
14. Adachi K, Klausner JD, Bristow CC, Xu J, Ank B, Morgado MG, et al. Chlamydia and Gonorrhea in HIV-Infected Pregnant Women and Infant HIV Transmission. Sex Transm Dis. 2015; 42(10):554–65. Epub 2015/09/16. PubMed Central PMCID: PMCPMC4571193. https://doi.org/10.1097/OLQ.0000000000000340 PMID: 26372927
15. World Health Organization: Guidelines For The Management of Sexually Transmitted Infections. Geneva, Switzerland, 1 February 2004. ISBN 9241546263.
16. Pettifor A, Walsh J, Wilkins V, Raghunathan P. How effective is syndromic management of STDS?: A review of current studies. Sex Transm Dis. 2000; 27(7):371–85. Epub 2000/08/19. PMID: 10949428

17. Fonck K, Kidula N, Jaoko W, Estambale B, Claey s P, Ndinya-Achola J, et al. Validity of the vaginal discharge algorithm among pregnant and non-pregnant women in Nairobi, Kenya. Sexually transmitted infections. 2000; 76(1):33–8. PubMed Central PMCID: PMC1760552. https://doi.org/10.1136/sti.76.1.33 PMID: 10817066

18. Gomih-Alakija A, Ting J, Mugo N, Kwatampora J, Getman D, Chitwa M, et al. Clinical characteristics associated with Mycoplasma genitalium among female sex workers in Nairobi, Kenya. Journal of clinical microbiology. 2014; 52(10):3660–6. Epub 2014/08/08. PubMed Central PMCID: PMCPMC4187795. https://doi.org/10.1128/JCM.00850-14 PMID: 25100823

19. Kohli R, Konya WP, Obura T, Stones W, Revathi G. Prevalence of genital Chlamydia infection in urban women of reproductive age, Nairobi, Kenya. BMC research notes. 2013; 6:44. PubMed Central PMCID: PMC3570388. https://doi.org/10.1186/1756-0500-6-44 PMID: 23375142

20. Maina AN, Kimani J, Anzala O. Prevalence and risk factors of three curable sexually transmitted infections among women in Nairobi, Kenya. BMC research notes. 2016; 9(1):193. Epub 2016/03/31.

21. Nyiro JU, Sanders EJ, Ngetsa C, Wale S, Awuondo K, Bukusi E, et al. Seroprevalence, predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus Type 2 infection in semi-urban women in Kilifi, Kenya. BMC Infectious Diseases. 2011; 11:155–. https://doi.org/10.1186/1471-2334-11-155 PMID: 21627803

22. Scott JAG, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, et al. Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). International Journal of Epidemiology. 2012; 41(3):650–7. PubMed Central PMCID: PMC3396317. https://doi.org/10.1093/ije/dys062 PMID: 22544844

23. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. Journal of clinical microbiology. 1991; 29(2):297–301. PubMed Central PMCID: PMCPMC3396317. https://doi.org/10.1186/1471-2334-1-155 PMID: 21627803

24. Ministry of Health Kenya, National guidelines for Reproductive Tract Infection Services. 2006. https://www.k4health.org/toolkits/kenya-health/national-guidelines-reproductive-tract-infection-services.

25. Duncan S, Thiongo AN, Macharia M, Waruuru L, Mwarumba S, Mvera B, et al. High prevalence of quinolone resistance in Neisseria gonorrhoeae in coastal Kenya. Sexually transmitted infections. 2011; 87 (3):231. Epub 2011/02/11. https://doi.org/10.1136/sti.2010.048777 PMID: 21307154

26. Cools P, Jespers V, Hardy L, Crucitti T, Delany-Morettle S, Mwaura M, et al. A Multi-Country Cross-Sectional Study of Vaginal Carriage of Group B Streptococci (GBS) and Escherichia coli in Resource-Poor Settings: Prevalences and Risk Factors. PloS one. 2016; 11(1):e0148052. Epub 2016/01/27. PubMed Central PMCID: PMCPMC4727807. https://doi.org/10.1371/journal.pone.0148052 PMID: 26881897

27. Kohli R, Konya WP, Obura T, Stones W, Revathi G. Prevalence of genital chlamydia infection in urban women of reproductive age, Nairobi, Kenya. BMC research notes. 2013; 6(1):1–5.

28. Chersich MF, Kley N, Luchters SM, Njeru C, Yard E, Othigo MJ, et al. Maternal morbidity in the first year after childbirth in Mombasa Kenya; a needs assessment. BMC pregnancy and childbirth. 2009; 9:51. Epub 2009/11/07. PubMed Central PMCID: PMCPm c2777848. https://doi.org/10.1186/1471-2393-9-51 PMID: 19891784

29. Fichorova RN, Buck OR, Yamamoto HS, Fashemi T, Dawood HY, Fashemi B, et al. The villain team-up of Trichomonas vaginalis and bacterial vaginosis alter innate immunity in concert. Sexually transmitted infections. 2013; 89(6):460–6. Epub 2013/08/02. PubMed Central PMCID: PMCPMC3746192. https://doi.org/10.1136/sextrans-2013-051052 PMID: 23903808

30. Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet. 1998; 351 (9087):213–4. Epub 1998/02/05.

31. McClleland RS, Sangare L, Hassan WM, Lavour E, Mandalika K, Kiarie J, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. The Journal of infectious diseases. 2007; 195 (5):696–702. Epub 2007/01/31. https://doi.org/10.1086/511278 PMID: 17262712

32. Kimanga DO, Ogola S, Umuro M, Ng’ang’a A, Kimondo L, Murithi P, et al. Prevalence and incidence of HIV infection, trends, and risk factors among persons aged 15–64 years in Kenya: results from a nationally representative study. Journal of acquired immune deficiency syndromes . 2014; 66 Suppl 1:S13–26.

33. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2003; 36(5):663–6. Epub 2003/02/21.

34. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnosis criteria and microbial and epidemiologic associations. Am J Med. 1983; 74(1):14–22. Epub 1983/01/01. PMID: 6600371

PLOS ONE | https://doi.org/10.1371/journal.pone.0175166 March 31, 2017 15 / 16
35. Madhivanan P, Krupp K, Hardin J, Karat C, Klausner JD, Reingold AL. Simple and inexpensive point-of-care tests improve diagnosis of vaginal infections in resource constrained settings. Tropical medicine & international health: TM & IH. 2009; 14(6):703–8. Epub 2009/04/28. PubMed Central PMCID: PMCPMC3625926.

36. Balkus JE, Manhart LE, Lee J, Anzala O, Kimani J, Schwebke J, et al. Periodic Presumptive Treatment for Vaginal Infections May Reduce the Incidence of Sexually Transmitted Bacterial Infections. The Journal of infectious diseases. 2016; 213(12):1932–7. Epub 2016/02/26. PubMed Central PMCID: PMCPMC4878720. https://doi.org/10.1093/infdis/jiw043 PMID: 26908758

37. Rafferty H, Ngoi C, Wahome E, Oduor C, van der Elst E, Berger R, et al. Assessing Training Needs of Clinical Officers to Target Acute HIV Infection Evaluation of Adult Patients Seeking Urgent Healthcare in Kenya. R4P2016.

38. Terris-Prestholt F, Vickerman P, Torres-Rueda S, Santesso N, Sweeney S, Mallma P, et al. The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia. International Journal of Gynaecology and Obstetrics. 2015; 130(Suppl 1):S73–S80.

39. Unger JA, Matemo D, Pintye J, Drake A, Kinuthia J, McClelland RS, et al. Patient-Delivered Partner Treatment for Chlamydia, Gonorrhoea, and Trichomonas Infection Among Pregnant and Postpartum Women in Kenya. Sexually transmitted diseases. 2015; 42(11):637–42. https://doi.org/10.1097/OLQ.0000000000000355 PMID: 26462189

40. Ma Q, Ono-Kihara M, Cong L, Xu G, Pan X, Zamani S, et al. Early initiation of sexual activity: a risk factor for sexually transmitted diseases, HIV infection, and unwanted pregnancy among university students in China. BMC Public Health. 2009; 9:111. Epub 2009/04/23. PubMed Central PMCID: PMCPMC2744603. https://doi.org/10.1186/1471-2458-9-111 PMID: 19383171

41. Chan PA, Robinette A, Montgomery M, Almonte A, Cu-Uvin S, Lonks JR, et al. Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature. Infectious diseases in obstetrics and gynecology. 2016. PubMed Central PMCID: PMCPMC4913006.

42. Kenya National Bureau of Statistics and Society for International Development. Exploring Kenya’s Inequality—Pulling apart or Pooling together?. 2013. http://www.knbs.or.ke/index.php?option=com_phocadownload&view=category&id=114:exploring-kenyas-inequality&Itemid=599.

43. El Aila NA, Tency I, Saerens B, De Backer E, Cools P, dos Santos Santos ML, et al. Strong correspondence in bacterial loads between the vagina and rectum of pregnant women. Research in microbiology. 2011; 162(5):506–13. Epub 2011/04/26. https://doi.org/10.1016/j.resmic.2011.04.004 PMID: 21513795

44. Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandeputte J, Buve A. Trichomonas vaginalis is highly prevalent in adolescent girls, pregnant women, and commercial sex workers in Ndola, Zambia, Sex Transm Dis. 2010; 37(4):223–7. https://doi.org/10.1097/OLQ.0b013e3181c21f93 PMID: 19940808

45. Pereira-Neves A, Benchimol M. Trichomonas vaginalis: in vitro survival in swimming pool water samples. Exp Parasitol. 2008; 118(3):438–41. Epub 2007/10/24. https://doi.org/10.1016/j.exppara.2007.09.005 PMID: 17949719

46. Gomes Naveca F, Sabido M, Amaral Pires de Almeida T, Araújo Veras E, Contreras Mejía MC, Galban E, et al. Etiology of Genital Ulcer Disease in a Sexually Transmitted Infection Reference Center in Manaus, Brazilian Amazon. PloS one. 2013; 8(5):e63953. https://doi.org/10.1371/journal.pone.0063953 PMID: 23704961

47. O’Farrell N, Hoosen AA, Coetzee KD, van den Ende J. Genital ulcer disease: accuracy of clinical diagnosis and strategies to improve control in Durban, South Africa. Genitourinary medicine. 1994; 70(1):7–11. Epub 1994/02/01. PubMed Central PMCID: PMCPMC1195171. PMID: 8300105

48. Brown JE, Brown RC. Traditional intravaginal practices and the heterosexual transmission of disease: a review. Sex Transm Dis. 2000; 27(4):183–7. Epub 2000/04/27. PMID: 10782738